Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers
Mingxing Hu, Yujue Li, Jiaxuan Li, Haoxuan Zhou, Chengyali Liu, Zi Liu, Youling Gong, Binwu Ying, Yongmei Xie
Topics & Concepts
In vivoChemistryCancerPharmacologyGrowth inhibitionIn vitroIC50Cancer researchInternal medicineMedicineBiologyBiochemistryBiotechnologyProtein Degradation and InhibitorsPeptidase Inhibition and AnalysisMultiple Myeloma Research and Treatments